Clinical trial
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to…
NCT00323570 · Novo Nordisk A/S, Industry · Withdrawn
Key facts
| NCT number | NCT00323570 |
|---|---|
| Title | Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma |
| Official title | A Multi-center, Randomized, Double-blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®/ NiaStase®) in the Treatment of Refractory Bleeding in Severely Injured Trauma Patients |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acquired Bleeding Disorder, Trauma |
| Intervention type | Drug |
| Interventions | activated recombinant human factor VII |
| Enrollment | 0 |
| Start date | May 1, 2006 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | May 9, 2006 |
| Last update posted | Jun 27, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: